未知生产厂商
Riltozinameran is a component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineage BA.1.
Riltozinameran is a component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineage BA.1.
Riltozinameran is a nucleoside-modified mRNA encapsulated in lipid nanoparticles that facilitate the delivery of the mRNA into human cells. Once inside the host cells, the mRNA is translated by host machinery to produce a modified SARS-CoV-2 spike (S) protein - specifically the S protein of the Omicron BA.1 variant lineage - which is subsequently recognized by the host immune system. Both neutralizing antibody and cellular immune responses are elicited in response to the vaccine, which helps protect against SARS-CoV-2 infection.
Riltozinameran, in combination with tozinameran (Comirnaty Original / Omicron BA.1), is indicated in patients ≥12 years of age as a booster dose for active immunization against COVID-19 caused by SARS-CoV-2. It may be given 3 to 6 months after completion of a primary course of Comirnaty and/or a previous booster dose of Comirnaty.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
